Page 228 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 8
16. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94(6):640-645.
17. Ten Brink MH, Van der Straaten T, Bouwsma H, Baak-Pablo R, Guchelaar HJ, Swen JJ. Pharmacogenetics in transplant patients: mind the mix. Clin Pharmacol Ther. 2013;94(4):443- 444.
18. Federa. Federation of Dutch Medical Scientific Societies. www.federa.org.
19. NCI. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.03. https:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf, 5 May 2017.
20. van Kuilenburg AB, Muller EW, Haasjes J, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res.
2001;7(5):1149-1153.
21. Van Kuilenburg ABP, Meijer J, Mul ANPM, et al. Intragenic deletions and a deep intronic mutation
affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms
causing 5-fluorouracil toxicity. Hum Genet. 2010;128(5):529-538.
22. Rommers MK, Zwaveling J, Guchelaar HJ, Teepe-Twiss IM. Evaluation of rule effectiveness and
positive predictive value of clinical rules in a Dutch clinical decision support system in daily
hospital pharmacy practice. Artif Intell Med. 2013;59(1):15-21.
23. Di Francia R, De Lucia L, Di Paolo M, et al. Rational selection of predictive pharmacogenomics
test for the Fluoropyrimidine/Oxaliplatin based therapy. Eur Rev Med Pharmacol Sci.
2015;19(22):4443-4454.
24. Boisdron-Celle M, Capitain O, Metges J-P, et al. Severe Fluoropyrimidines toxicities: a simple and
effective way to avoid them. Screen effectively for DPD deficiencies. Ann Oncol. 2012;Conference:
37th Congress of the European Society for Medical Oncology (ESMO).
25. Swen JJ, Nijenhuis M, De BA, et al. Pharmacogenetics: from bench to byte--an update of
guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.
26. KNMP. Royal Dutch Society for the Advancement of Pharmacy. Background information
Pharmacogenetics - Dihydropyriminde dehydrogenase (DPD). . 2015; https://kennisbank.knmp. nl/files/farmacogenetica/Achtergrondteksten/dpd.pdf.
226